| Document |
Document Title |
|
WO/2023/125540A1 |
Provided are a pyrazole-1(2H)-phthalazinone compound and an application thereof as a PRMT5·MTA complex inhibitor in the preparation of a drug for treating related diseases.
|
|
WO/2023/127805A1 |
In the production of crops in agriculture, horticulture, and the like, the occurrence of damage by pests and the like has been still a major issue, and therefore the development of new agricultural/horticultural pesticides has been deman...
|
|
WO/2023/125276A1 |
Provided in the present invention are an organic compound and a use thereof, the molecular bulk density thereof being improved through the design of the molecular structure, and the compound having excellent hole transport properties; th...
|
|
WO/2023/122778A1 |
Disclosed herein are oxime compounds having the structure of Formula (I'): or a pharmaceutically acceptable salt, solvate, hydrate, isomer, tautomer, racemate, or isotope thereof, wherein L1, L2, R1, R2, R3, R4, R7, n, and r are as defin...
|
|
WO/2023/118875A1 |
The invention relates to a compound of formula (I) which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3
-yl)methyl)phthalazin-1(2H)- one; or a salt and/or solvate thereof; and to its use in treating or preventing an infl...
|
|
WO/2023/116902A1 |
Disclosed are an SOS1 inhibitor represented by formula (X), or a pharmaceutically acceptable salt, isotopic variant, tautomer, stereoisomer, prodrug, polymorph, hydrate, or solvate thereof. Further disclosed are a preparation method for ...
|
|
WO/2023/111996A1 |
Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating cancers can include administering an effective amount of at least one ...
|
|
WO/2023/108292A1 |
The present document relates to tetrahydropyridazine compounds, pharmaceutical compositions comprising the same and their use in the treatment or prevention of diseases and disorders associated with the cannabinoid CB1 receptor. For exam...
|
|
WO/2023/114818A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/104155A1 |
The present disclosure relates to compounds of formula (I) and formula (II), or salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or polymorphs of said compounds, and the uses of same. The present discl...
|
|
WO/2023/102162A1 |
Described herein are novel compounds, compositions and methods for treatment of diseases including cancer using such compounds, compositions, and methods. The compounds include those of Formula (I):
|
|
WO/2023/097386A1 |
The present invention relates to selective HDAC6-inhibiting N-acylhydrazone compounds. More specifically, the present invention relates to N-acylhydrazone compounds of formula (I), and to the methods for producing same, compositions, kit...
|
|
WO/2023/098439A1 |
A pyrazole derivative, and a preparation method therefor and a use thereof in medicine. In particular, the present invention relates to a PRMT5 inhibitor having a structure shown in formula (I), a preparation method therefor, a pharmaceu...
|
|
WO/2023/094830A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion ch...
|
|
WO/2023/093686A1 |
Disclosed in the present invention are a benzo[c]cinnoline skeleton diimide ligand and a preparation method therefor. The ligand has the structure represented by general formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 are as...
|
|
WO/2023/094303A1 |
Compounds of Formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2023/088987A1 |
The application relates to pyridazine derivatives of the general formula (Ib), to pharmaceutical compositions comprising the compounds and to their use in the treatment of diseases and conditions such as asthma, COPD, Parkinson's and Alz...
|
|
WO/2023/089049A2 |
A compound of Formula (I) wherein the substituents are as defined in claim 1, useful as pesticides, especially as fungicides.
|
|
WO/2023/084311A1 |
The invention relates to new 1:1 olaparib:hydroxybenzoic acid cocrystals. The invention also relates to new 2:1 olaparib:hydroxybenzoic acid cocrystals which may contain no water (anhydrous) or may optionally be hydrated. The invention a...
|
|
WO/2023/086799A1 |
The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of ...
|
|
WO/2023/079294A1 |
The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: whe...
|
|
WO/2023/078915A1 |
The present invention relates to Bis(hetero)aryl thioether (thio)amides derivatives and the uses thereof for controlling phytopathogenic microorganisms such as phytopathogenic fungi. It also relates to processes and intermediates for pre...
|
|
WO/2023/077070A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/072849A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2023/073966A1 |
This invention addresses the problem of developing a reaction control method for an inverse electron demand Diels-Alder reaction, and a method for producing a cyclocondensation reaction product utilizing a reaction-controlled inverse ele...
|
|
WO/2023/066377A1 |
A compound represented by formula (I), a solvate thereof, a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. The nitrogen-co...
|
|
WO/2023/051749A1 |
The present invention relates to an AAK1 inhibitor and the use thereof. Specifically, the present invention relates to a compound as represented by formula I, a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt o...
|
|
WO/2023/051761A1 |
Provided are a substituted heteroaryl phthalazine derivative as shown in formula (I-0), a use thereof as an NLRP3 inhibitor, and a preparation method therefor; the derivative has relatively good NLRP3 inhibitory activity.
|
|
WO/2022/170974A9 |
Provided are a compound of formula (I) that inhibit the activity of PARP7, a stereoisomer thereof, a deuterated derivative thereof, or a pharmaceutically acceptable salt thereof, an intermediate to prepare the compound, a process to prep...
|
|
WO/2023/043040A1 |
The present invention provides a novel compound for a light-emitting device, and an organic light-emitting device comprising same.
|
|
WO/2023/044171A1 |
The disclosure provides compounds with nitrile warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with nitrile warheads are prov...
|
|
WO/2023/043753A1 |
Disclosed herein are compounds which can act modulators of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating diseases and disorders, such as cancer and viral infections, using the compounds disclosed ...
|
|
WO/2023/040686A1 |
A pyridazinone compound, a preparation method, a herbicide composition and the use thereof. The present invention specifically relates to a pyridazinone compound represented by general formula I or an agriculturally acceptable salt there...
|
|
WO/2023/036934A1 |
The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulphonyl-pyridine derivatives of formula (I),wherein the variables are as defined in the description and in the claims, which can be used as antiparasitic agents...
|
|
WO/2023/039047A1 |
The disclosure relates to compounds that act as inhibitors of interleukin 1 (IL-1) receptor-associated kinase 4 (IRAK4); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorder...
|
|
WO/2023/029833A1 |
An SOS1 inhibitor, and a preparation method therefor and the use thereof. The SOS1 inhibitor has a structural formula as represented by formula (I), wherein the symbols and variables are as defined in the description. The SOS1 inhibitor ...
|
|
WO/2023/022497A1 |
Provided are a novel compound of chemical formula I and a use thereof for preventing or treating SOS1-related diseases. A novel compound according to an aspect of the present invention inhibits interaction between SOS1 and a RAS family p...
|
|
WO/2023/020457A1 |
Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compou...
|
|
WO/2023/023242A1 |
Disclosed are compounds of Formula 1 including all geometric and stereoisomers, N- oxides, and salts thereof, wherein Q1, Q2 and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 an...
|
|
WO/2023/006013A1 |
Disclosed are a compound serving as a PARP7 inhibitor, and a use thereof in preparing a drug for treating relevant diseases. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof....
|
|
WO/2023/003002A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of the pres...
|
|
WO/2023/288002A1 |
The present invention concerns phthalazinone-based compounds of that inhibit the PARP-1 protein, the compounds having Formula (I):
|
|
WO/2023/275366A1 |
The specification generally relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, where R1, R2A, R2B, R2C, R2D, W, X, Y, and Z have the meanings defined herein. Such compounds are useful in inhibiting NLRP3 ...
|
|
WO/2023/277594A1 |
The present invention provides a novel compound for a capping layer, and an organic light-emitting device comprising same.
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2023/276813A1 |
The present invention addresses the problem of providing a pyridazinone compound which has excellent bactericidal/antibacterial activity and excellent safety, while being industrially beneficially synthesized; and an agricultural/horticu...
|
|
WO/2023/278438A1 |
Described herein are NLRP3 modulators and methods of utilizing NLRP3 modulators in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2022/271679A1 |
The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating ca...
|
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/258992A1 |
The invention provides compounds of formula (I), stereoisomers, and pharmaceutically acceptable salts thereof for use in the treatment or prevention of hypertension: wherein: R1 and R2 are independently selected from H, halogen, C1-6 alk...
|
